Continuing its push overseas, Endonovo Therapeutics has announced a strategic partnership with a Taiwanese company to distribute its flagship product in that country. The electrical medical device company in Woodland Hills hopes the partnership will further expand its global footprint. Endonovo already has established itself in Canada and China, a spokesperson for the company said, and has its sights on South America for its next expansion. The company’s primary device, named SofPulse, uses electronic pulses to assist with physical therapy after surgery and to treat chronic ailments. The Taiwanese company, Evermed Medical Enterprise, which specializes in medical device distribution, will work to obtain Taiwan Food and Drug Administration approvals and registration for SofPulse as part of the partnership. “Evermed has an established sales and distribution network throughout Taiwan specific to the operative and postoperative surgical market,” Alan Collier, chief executive of Endonovo, said in a statement. “Endonovo’s international expansion of SofPulse devices into that market is a perfect fit allowing us to establish a solid distribution presence in Taiwan and future expansion into other international markets.” “Our sales and distribution offices and teams are strategically located in Taipei, Taichung, Kaohsiung/Tainan, which allows us to effectively service Taiwan’s 23-million person population, hospitals and medical centers,” added George Wang, chief executive of Evermed. “The patients, doctors and hospitals we have established relationships with throughout Taiwan will love this product and its effectiveness in reducing opioid use and the improved recovery times after surgical procedures.” Shares of Endonovo (ENDV) went down 1 cent or about 9 percent on Wednesday and closed at 14 cents on the over-the-counter market.
